Iron- Deficiency in Pregnancy: Our Experience in Intravenous Iron Treatment with Ferric Carboxymaltose, Iron Sucrose and Ferric Hydroxid Dextran Complex by Yordanova, Diana & Nikolov, Asen
 International Journal of Sciences: 
Basic and Applied Research 
(IJSBAR) 
 
ISSN 2307-4531 
(Print & Online) 
 
http://gssrr.org/index.php?journal=JournalOfBasicAndApplied 
--------------------------------------------------------------------------------------------------------------------------- 
191 
 
Iron- Deficiency in Pregnancy: Our Experience in 
Intravenous Iron Treatment with Ferric Carboxymaltose, 
Iron Sucrose and Ferric Hydroxid Dextran Complex 
Diana Yordanovaa*, Asen Nikolovb 
a,bUniversity Hospital of Obstetrics and Gynecology “Maichin dom” 2, Zdrave St 
1430 Sofia, Bulgaria 
 
 
 
Abstract  
Anemia is one of the most prevalent nutritional deficiency problems affecting pregnant women. The high 
prevalence of iron and other micronutrient deficiencies among women during pregnancy in developing countries 
is of concern and maternal anemia is still a cause of considerable perinatal morbidity and mortality. Severely 
anemic pregnant women may require blood transfusion, which is not always feasible in under- resourced 
settings, and it may even carry some risks for the woman. To avoid this, intravenous preparations are used in the 
management of moderate iron- deficiency anemia in pregnancy. Our data confirmed that intravenous 
administration elevated the hemoglobin and they were well tolerable. Iron sucrose is the preferred and it has 
demonstrated a high success rate. Recently, ferric carboxymaltose and ferric hydroxide dextran complex take 
place in the treatment of iron- deficiency anemia in pregnancy. There are no investigations in Bulgaria that 
compared the effectiveness of the three intravenous preparations for treatment of moderate iron- deficiency 
anemia during the second and third trimester of pregnancy. 
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1. Introduction 
Iron deficiency is the most widespread nutritional deficiency in the world [1]. It is the most common cause of 
anemia during pregnancy. The World Health Organization defines anemia in pregnancy as a hemoglobin level 
below 110 g/l in the first and third trimester and below 105 g/l in the second trimester [2]. 
Iron deficiency may be effectively diagnosed in most cases by serum ferritin level [3]. There are two types of 
iron deficiency: absolute (iron stores are reduced or depleted and serum ferritin levels are low, below 20 µg/l) 
and functional (when the mobilization of iron from the macrophages is not fast enough to fulfill the increased 
demands of bone marrow, despite adequate total body stores). When the functional iron deficiency is a result of 
the presence of inflammation, patients have normal or high serum ferritin levels and elevated serum hepcidine 
[4]. The last stage of absolute iron deficiency is the iron- deficiency anemia. It can be mild, moderate and severe 
according to the concentration of hemoglobin. The anemia is moderate when the hemoglobin level is between 
99 g/l and 70 g/l. A number of oral and parenteral iron preparations have been used in the treatment of iron- 
deficiency anemia for many years [5]. Whereas oral preparations are adequate for the treatment of mild forms of 
iron- deficiency anemia, parenteral iron therapy is necessary in situations where there is need for rapid repletion 
of iron stores, anemia is moderate to severe, or in cases of malabsorption or intolerance to oral iron therapy [5, 
6]. Iron formulations suitable for intravenous administration need to achieve a balance between effectiveness 
and safety [7].  
Ferric carboxymaltose [8] is a new intravenous  iron formulation promising to be more effective than ferric 
hydroxide dextran complex and as safe as iron sucrose. There isn’t such an investigation of the intravenous 
management of iron- deficiency anemia in pregnancy in our country. 
2. Materials and methods  
It is a prospective analysis of 68 pregnant women, collected for a year. The inclusion criteria are: symptomatic 
iron- deficiency anemia unresponsive or intolerable to oral iron substitution; second to third trimester; moderate 
anemia. The exclusion criteria are: functional iron deficiency; multiple pregnancies; first trimester; mild and 
severe forms of iron- deficiency anemia (hemoglobin level > 100 g/l and below 70 g/l). The investigated 
pregnant women are divided in three groups: 30 who are treated with iron sucrose, 20 who are treated with ferric 
hydroxide dextran complex and 18 who are treated with ferric carboxymaltose.  
The preparations are administrated as an intravenous infusion of 200 mg iron daily, three times a week. Data are 
collected on the pre- treatment serum hemoglobin and ferritin and same data collected at 24 and 72 post- 
infusion hours and at one week. Primary endpoint was to evaluate the maternal safety and tolerability. 
Secondary endpoint was to assess efficacy of the treatment. 
3.  Results and discussion 
The mean rise of hemoglobin value was 23.1 g/l for ferric carboxymaltose, 15.5 g/l for ferric hydroxide dextran 
complex and 9.8 g/l for iron sucrose. Pre-infusion hemoglobin and ferritin levels were comparable in the three 
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groups. Mean pre- infusion values of ferritin were 13.3 µg/l. At 24 post- infusion hours there is no significant 
rise of the hemoglobin and ferritin values in the three groups.  At 72 post- infusion hours, the mean hemoglobin 
and ferritin rise in the ferric carboxymaltose group was 8.4 g/l and 10.4 µg/l, 3.2 g/l and 7.1 µg/l in the ferric 
hydroxide dextran complex group and 2.9 g/l and 5.3 µg/l in the iron sucrose group. 
 At a week, the total rise in hemoglobin and ferritin was 15.7 g/l and 13.1 µg/l  in the ferric carboxymaltose 
group, 13.4 g/l and 10.5 µg/l in the ferric hydroxide dextran complex group and 8.5 g/l and 6.8 µg/l in the iron 
sucrose group (see table 1 and table 2). 
Table 1: Mean values of hemoglobin in the ferric carboxymaltose, ferric hydroxide dextran complex and iron 
sucrose groups before and after intravenous infusions. 
Intravenous 
preparation 
Mean pre- infusion 
values of 
hemoglobin 
Mean hemoglobin’ 
values at 24 post- 
infusion hours 
Mean hemoglobin’ 
values at 72 post- 
infusion hours 
Mean hemoglobin’ 
values at a week 
Ferric 
carboxymaltose 
82.3 g/l 81.3 g/l 89.7 g/l 105.4 g/l 
Ferric hydroxide 
dextran complex 
86.2 g/l 85.1 g/l 88.3 g/l 101.7 g/l 
Iron sucrose 87.4 g/l 85.8 g/l 88.7 g/l 97.2 g/l 
 
Table 2: Mean values of ferritin in the ferric carboxymaltose, ferric hydroxide dextran complex and iron 
sucrose groups before and after intravenous infusions. 
Intravenous 
preparation 
Mean pre- infusion 
values of ferritin 
Mean ferritin’ 
values at 24 post- 
infusion hours 
Mean ferritin’ 
values at 72 post- 
infusion hours 
Mean ferritin’ 
values at a week 
Ferric 
carboxymaltose 
12.3 µg/l 13.2 µg/l 22.7 µg/l 25.4 µg/l 
Ferric hydroxide 
dextran complex 
13.2 µg/l 14.1 µg/l 20.3 µg/l 23.7 µg/l 
Iron sucrose 14.4 µg/l 14.8 µg/l 19.7 µg/l 21.2 µg/l 
 
The incidence of drug- related adverse events was low and mostly mild in the three groups. Mild adverse events 
(headache, flushing, chills, nausea, tachycardia, wheezing, myalgia) occurred in 2.2 % for ferric 
carboxymaltose, in 3.4 % for ferric dextran complex and in 2.9 % for iron sucrose (see table 3). 
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Table 3: The incidence of drug- related adverse events in the ferric carboxymaltose, ferric hydroxide dextran 
complex and iron sucrose group. 
 Ferric 
carboxymaltose 
Ferric hydroxide 
dextran complex 
Iron sucrose 
Headache 5.6 % 6.2 % 4.1 % 
Flushing 3.4 % 5.8 % 6.3 % 
Chills 1.2 % 2.1 % 2.8 % 
Nausea 2.0 % 0.9 % 1.5 % 
Tachycardia 2.7 % 4.3 % 3.5 % 
Wheezing 0.2 % 3.2 % 1.2 % 
Myalgia 0.6 % 1.0 % 0.7 % 
 
4. Conclusion 
Three preparations appear effective and safe, with low risk of serious adverse effects and side- effects. Ferric 
carboxymaltose administration in pregnant women is well tolerated and is not associated with any relevant 
clinical safety concerns. Ferric carboxymaltose has a comparable safety profile to iron sucrose but offers the 
advantage of a much higher iron dosage at a time reducing the need for repeated applications and increasing 
patients' comfort. Ferric carboxymaltose is the drug of choice, if intravenous iron treatment becomes necessary 
in the second or third trimester of pregnancy. 
References 
[1] Zimmermann M. B.. R. F. Hurrell. Nutritional iron deficiency (2007) Lancet 370: 511- 520. 
[2] de Benoist B., E. McLean, I. Egli et al. Worldwide prevalence of anemia 1993- 2005: WHO global 
database on anemia (2008) Available at:  
http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf. 
[3] World Health Organization. Serum Ferritin Concentrations for the Assessment of Iron Status and Iron 
Deficiency in Populations. Geneva: World Health Organization (2011). Accessed at:  
http://www.who.int/vmnis/indicators/ferritin/en/  
[4] Nemeth E., T. Ganz. Hepcidin and iron- loading anemias (2006) Haematologica; 91: 727- 732. 
[5] Breymann C., C. Honegger C., W. Holzgreve et al. Diagnosis and treatment of iron- deficiency anemia 
during pregnancy and postpartum (2010) Arch Gynecol Obstet; 282: 577- 580. 
[6] Reveiz L., G. M. L. Gyte, L. G. Cuervo, A. Casasbuenas. Treatments for iron-deficiency anaemia in 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 30, No  1, pp 191-195 
195 
 
pregnancy (2011) Cochrane Database Syst Rev. 10: CD003094. 
 [7] Crichton R., B. G. Danielson, P. Geisser et al. Iron therapy with special emphasis on intravenous 
administration (2008) Uni- Med Verlag AG, London, Boston. 
[8] Bernd F., J. Collingwood, N. A. Hodyl, G. Dekker. Intravenous ferric carboxymaltose for anemia in 
pregnancy (2014) BMC Pregnancy and Childbirth;14: 115  doi:10.1186/1471-2393-14-115 
 
 
 
 
 
 
 
 
